We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Liver Values Elevated in Overweight Children with Gene Mutation

By LabMedica International staff writers
Posted on 07 Jul 2014
Print article
Image: Histopathology of non-alcoholic fatty liver disease showing the liver with prominent macrovesicular steatosis (Photo courtesy of Nephron).
Image: Histopathology of non-alcoholic fatty liver disease showing the liver with prominent macrovesicular steatosis (Photo courtesy of Nephron).
Genetic polymorphism has been strongly associated with liver fat content and plasma alanine aminotransferase levels in obese adults and children, but little is known about these relationships in normal weight individuals.

Plasma levels of liver enzymes alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) that are widely used in clinical practice for the diagnostics of liver diseases have also been suggested as useful tools in the screening for pediatric non-alcoholic fatty liver disease (NAFLD).

Scientists at the University of Eastern Finland (Kuopio, Finland) studied a population sample of 481 Caucasian children aged 6 to 8 years who were examined at baseline and 419 children reexamined after two year follow-up. Altogether, 58 (12%) of 481 children at baseline and 71 (17%) of 419 children (205 girls and 214 boys) after 2-year follow-up were overweight.

Kinetic methods were used to analyze plasma activities of ALT and GGT (Roche Diagnostics Co., Mannheim, Germany). Genomic DNA was isolated from the blood mononuclear cells using the QIAamp DNA Blood kit (Qiagen, Hilden, Germany). The Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) allele rs738409 was genotyped using an allele-specific polymerase chain reaction (PCR) assay. PNPLA3 148M polymorphisms were also investigated.

Of the 481 children examined at baseline, 283 (58.8%) were 148I homozygotes, 173 (36.0%) were I148M heterozygotes and 25 (5.2%) were 148M homozygotes. Of the 419 children re-examined after 2-year follow-up, 244 (58.2%) were 148I homozygotes, 153 (36.5%) were heterozygotes and 22 (5.3%) were 148M homozygotes. There were no differences in the genotype distributions of the rs738409 polymorphism between normal weight children and overweight children. Overweight children had higher plasma ALT levels at baseline and after two year follow-up and a larger increase in plasma ALT activity during two year follow-up than normal weight children adjusted for age, sex, body height, carrying the PNPLA3 148M allele.

The authors concluded that in healthy children the carriers of the 148M allele of the PNPLA3 rs738409 polymorphism have elevated plasma levels of ALT if they were overweight but not if they have a normal body weight. On the other hand, overweight children had higher plasma ALT levels than normal weight children even without the risk allele. These findings emphasize the early prevention of overweight particularly among children carrying the PNPLA3 148M allele to avoid liver fat accumulation and the development of NAFLD. The study was published on June 11, 2014, in the journal Pediatric Obesity.

Related Links:

University of Eastern Finland
Roche Diagnostics
Qiagen 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.